Arbeitsgruppe Neuroendokrine Tumoren/Karzinoide - Studien

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-NET-0112: Safety and Tolerability of Everolimus as second–line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 (WHO 2010) and neuroendocrine tumor G3 – an investigator inititated Phase II study (EVINEC)

AIO-assoziierte Studie
www.clinicaltrials.gov zur Studie

AIO-NET-0215/ass: Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)

AIO-assoziierte Studie
www.clinicaltrials.gov
zur Studie

AIO-NET-0116/ass: A Phase 3, prospective, randomized, double-blind, multi-center study of the efficacy and safety of lanreotide Autogel/Depot 120 mg plus BSC vs. placebo plus BSC for tumour control in subjects with well differentiated, metastatic and/or unresectable, typical or atypical, lung neuroendocrine tumours. (SPINET-Trial)

AIO-assoziierte Studie
www.clinicaltrials.gov
zur Studie

AIO-NET-0216/ass: Efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in well differentiated, metastatic or locally advanced, unresectable pancreatic or midgut neuroendocrine tumours having progressed radiologically while previously treated with lanreotide Autogel® 120 mg administered every 28 days. (CLARINET FORTE-Trial)